Human Papillomavirus Vaccine Market

Human Papillomavirus Vaccine Market (Indication: Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts, and Others) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Human Papillomavirus Vaccine Market Outlook 2031

  • The industry was valued at US$ 4.0 Bn in 2022
  • It is projected to grow a CAGR of 9.4% from 2023 to 2031 and reach US$ 9.1 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of HPV-related diseases is driving the global market. Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) across the world. Campaigns and initiatives by governments for the development and distribution of HPV vaccines to control the spread of HPV is another major factor propelling market expansion. Furthermore, increase in initiatives by governments is expected to bolster the global human papillomavirus vaccine market size during the forecast period.

Development of novel molecules targeting HPV offers lucrative opportunities to market players. Manufacturers are investing significantly in the development of new HPV vaccines for all age groups in order to increase market share.

Human Papillomavirus Vaccine Market

Global Human Papillomavirus Vaccine Market Overview

Human papillomavirus, also known as HPV, is a common virus that affects various parts of the body. HPV is a group of more than 200 related viruses, of which more than 40 strains are spread through direct sexual contact. HPV that affects genitals is generally a sexually transmitted infection (STI) which is passed via physical contacts.

Among these, two HPV strains cause genital warts, and about a dozen HPV types can cause certain types of cancer such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal. Generally, the body can find and clear out HPV, but in some cases the virus stays in the body for a long period of time, which can cause cancer.

HPV vaccines stimulate the body to produce antibodies that, in future encounters with HPV, bind to the virus and prevent it from infecting cells. The vaccine simply protects the body from getting any type of cancer caused due to HPV. As a result, getting vaccinated against HPV helps prevent cancer in both men and women.

Increase in Initiatives by Governments Boosting Market Progress

According to human papillomavirus vaccine market research, governments across the world are introducing several campaigns and initiatives for the development and distribution of HPV vaccines to control the spread of human papillomavirus.

Private organizations and government bodies are funding screening and immunization programs and distribution of HPV vaccines across various parts of the world. In January 2023, an article published in Vaccines Journal stated that the HPV vaccine is fully funded for children aged 11 years to 14 years and for 15- to 26-year-old females in Switzerland.

In January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign to increase HPV vaccination rates among young adults aged 18-26 years.

Global organizations, such as UNICEF, have made attempts to improve vaccine acceptance over the years. The Pan American Health Organization’s (PAHO) revolving fund and UNICEF supply division allows vaccinations to be procured at lower prices for various countries. PAHO and UNICEF purchase vaccines for roughly 40 states and around 100 countries each year, boosting the adoption rate of viral infection vaccine.

Rise in Prevalence of HPV-related Diseases Fueling Human Papillomavirus Vaccine Industry

HPV is the most common sexually transmitted infection (STI) in the world. Around 80% of all sexually active people are estimated to be infected by HPV at some point in their lives. Increase in cases of HPV-related diseases such as cervical cancer, anal cancer, vaginal cancer and others is expected to bolster the global human papillomavirus vaccine market demand during the forecast period.

According to HPV and Related Cancers report 2023, cervical cancer ranks as the 2nd most frequent cancer among women in India, and the 2nd most frequent cancer among women between 15 and 44. As per the same source, 123,907 women are diagnosed with cervical cancer in India each year.

Regional Outlook

North America accounted for the largest global human papillomavirus vaccine market share in 2022. This is ascribed to improved healthcare infrastructure and increase in cases of cervical cancer and other HPV-related cancers among the population.

A report published in 2022 by the American Cancer Society stated that 9,440 new anal cancers were diagnosed in the U.S. in the same year. Moreover, as per the Canadian Cancer Society, 1,450 Canadian women were diagnosed with cervical cancer in 2022.

According to an article published in February 2023 in the Human Vaccine and Immunotherapeutic Journal, HPV vaccination in the U.S. can start at age nine and last until age 26. Approximately 77% of teenagers 13 to 17 years old have received one or more doses of the HPV vaccine, and nearly 62% have finished the entire series. Significant coverage for HPV vaccine and early screening initiatives are expected to propel the human papillomavirus vaccine market growth in the region.

Analysis of Key Players

Major players are focusing on product launches and investment in research & development to increase the effectiveness of the human papillomavirus vaccine in adults. These companies are following the latest human papillomavirus vaccine market trends to avail lucrative revenue opportunities.

Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, AstraZeneca, Serum Institute of India Pvt. Ltd., Xiame Innovax Biotech CO., LTD., General Incorporated Foundation, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), and Bharat Biotechare are the prominent players in the global human papillomavirus vaccine market.

Key Developments in Global Human Papillomavirus Vaccine Market

  • In March 2023, Roche Diagnostics India and the Cancer Awareness Prevention and Early Detection Trust (CAPED) signed an agreement of a Memorandum of Understanding (MoU) with an aim to launch a cervical cancer screening program in India
  • In April 2022, Merck Canada received Health Canada's approval for an expanded indication of GARDASIL 9 ((Human Papillomavirus 9-valent Vaccine, Recombinant) in individuals 9 through 45 years of age to prevent infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.

Each of these companies has been profiled in the human papillomavirus vaccine market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Global Human Papillomavirus Vaccine Market Snapshot

Attribute Detail
Size in 2022 US$ 4.0 Bn
Forecast (Value) in 2031 US$ 9.1 Bn
Growth Rate (CAGR) 9.4%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Valence
    • Bivalent
    • Quadrivalent and Nonavalent
  • Indication
    • Cervical Cancer
    • Anal Cancer
    • Vaginal Cancer
    • Penile Cancer
    • Vulvar Cancer
    • Oropharyngeal Cancer
    • Genital Warts
    • Others
  • Distribution Channel
    • Physicians
    • Wholesalers
    • Physician Distributors
    • Government Entities
    • Public and Private Alliances
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASIAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Companies Profiled
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi
  • AstraZeneca
  • Serum Institute of India Pvt. Ltd.
  • Xiame Innovax Biotech CO., LTD.
  • General Incorporated Foundation
  • Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
  • Bharat Biotech
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global human papillomavirus vaccine market in 2022?

It was valued at US$ 4.0 Bn in 2022

How is the human papillomavirus vaccine business expected to grow by 2031?

It is anticipated to grow at a CAGR of 9.4% from 2023 to 2031

What are the key factors driving demand for human papillomavirus vaccine?

Increase in initiatives by governments and rise in prevalence of HPV-related diseases

Which was the largest human papillomavirus vaccine segment in 2022?

The quadrivalent and nonavalent segment accounted for the largest share in 2022

Which was the major region in the human papillomavirus vaccine landscape in 2022?

North America was the leading region in 2022

Who are the prominent human papillomavirus vaccine manufacturers?

Merck & Co., Inc., GlaxoSmithKline plc., Sanofi, AstraZeneca, Serum Institute of India Pvt. Ltd., Xiame Innovax Biotech CO., LTD., General Incorporated Foundation, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), and Bharat Biotech.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Human Papillomavirus Vaccine Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Valence, 2017–2031

            6.3.1. Bivalent

            6.3.2. Quadrivalent and Nonavalent

        6.4. Market Attractiveness Analysis, by Valence

    7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Indication, 2017–2031

            7.3.1. Cervical Cancer

            7.3.2. Anal Cancer

            7.3.3. Vaginal Cancer

            7.3.4. Penile Cancer

            7.3.5. Vulvar Cancer

            7.3.6. Oropharyngeal Cancer

            7.3.7. Genital Warts

            7.3.8. Others

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Physicians

            8.3.2. Wholesalers

            8.3.3. Physician Distributors

            8.3.4. Government Entities

            8.3.5. Public and Private Alliances

        8.4. Market Attractiveness Analysis, by Indication

    9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Valence, 2017–2031

            10.3.1. Bivalent

            10.3.2. Quadrivalent and Nonavalent

        10.4. Market Value Forecast, by Indication, 2017–2031

            10.4.1. Cervical Cancer

            10.4.2. Anal Cancer

            10.4.3. Vaginal Cancer

            10.4.4. Penile Cancer

            10.4.5. Vulvar Cancer

            10.4.6. Oropharyngeal Cancer

            10.4.7. Genital Warts

            10.4.8. Others

        10.5. Market Value Forecast, by Distribution Channel, 2017–2031

            10.5.1. Physicians

            10.5.2. Wholesalers

            10.5.3. Physician Distributors

            10.5.4. Government Entities

            10.5.5. Public and Private Alliances

        10.6. Market Value Forecast, by Country, 2017–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Valence

            10.7.2. By Indication

            10.7.3. By Distribution Channel

            10.7.4. By Country

    11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Valence, 2017–2031

            11.3.1. Bivalent

            11.3.2. Quadrivalent and Nonavalent

        11.4. Market Value Forecast, by Indication, 2017–2031

            11.4.1. Cervical Cancer

            11.4.2. Anal Cancer

            11.4.3. Vaginal Cancer

            11.4.4. Penile Cancer

            11.4.5. Vulvar Cancer

            11.4.6. Oropharyngeal Cancer

            11.4.7. Genital Warts

            11.4.8. Others

        11.5. Market Value Forecast, by Distribution Channel, 2017–2031

            11.5.1. Physicians

            11.5.2. Wholesalers

            11.5.3. Physician Distributors

            11.5.4. Government Entities

            11.5.5. Public and Private Alliances

        11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Valence

            11.7.2. By Indication

            11.7.3. By Distribution Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Valence, 2017–2031

            12.3.1. Bivalent

            12.3.2. Quadrivalent and Nonavalent

        12.4. Market Value Forecast, by Indication, 2017–2031

            12.4.1. Cervical Cancer

            12.4.2. Anal Cancer

            12.4.3. Vaginal Cancer

            12.4.4. Penile Cancer

            12.4.5. Vulvar Cancer

            12.4.6. Oropharyngeal Cancer

            12.4.7. Genital Warts

            12.4.8. Others

        12.5. Market Value Forecast, by Distribution Channel, 2017–2031

            12.5.1. Physicians

            12.5.2. Wholesalers

            12.5.3. Physician Distributors

            12.5.4. Government Entities

            12.5.5. Public and Private Alliances

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Valence

            12.7.2. By Indication

            12.7.3. By Distribution Channel

            12.7.4. By Country/Sub-region

    13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Valence, 2017–2031

            13.3.1. Bivalent

            13.3.2. Quadrivalent and Nonavalent

        13.4. Market Value Forecast, by Indication, 2017–2031

            13.4.1. Cervical Cancer

            13.4.2. Anal Cancer

            13.4.3. Vaginal Cancer

            13.4.4. Penile Cancer

            13.4.5. Vulvar Cancer

            13.4.6. Oropharyngeal Cancer

            13.4.7. Genital Warts

            13.4.8. Others

        13.5. Market Value Forecast, by Distribution Channel, 2017–2031

            13.5.1. Physicians

            13.5.2. Wholesalers

            13.5.3. Physician Distributors

            13.5.4. Government Entities

            13.5.5. Public and Private Alliances

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Valence

            13.7.2. By Indication

            13.7.3. By Distribution Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Valence, 2017–2031

            14.3.1. Bivalent

            14.3.2. Quadrivalent and Nonavalent

        14.4. Market Value Forecast, by Indication, 2017–2031

            14.4.1. Cervical Cancer

            14.4.2. Anal Cancer

            14.4.3. Vaginal Cancer

            14.4.4. Penile Cancer

            14.4.5. Vulvar Cancer

            14.4.6. Oropharyngeal Cancer

            14.4.7. Genital Warts

            14.4.8. Others

        14.5. Market Value Forecast, by Distribution Channel, 2017–2031

            14.5.1. Physicians

            14.5.2. Wholesalers

            14.5.3. Physician Distributors

            14.5.4. Government Entities

            14.5.5. Public and Private Alliances

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Valence

            14.7.2. By Indication

            14.7.3. By Distribution Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Merck & Co., Inc.

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. GlaxoSmithKline plc

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Sanofi

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. AstraZeneca

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Serum Institute of India Pvt. Ltd.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. Xiame Innovax Biotech Co., Ltd.

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. General Incorporated Foundation

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Bharat Biotechare

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 02: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 03: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 07: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 08: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 11: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 12: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 15: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 16: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 19: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 20: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031

    Table 23: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031

    Table 24: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

    Figure 02: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Valence, 2022

    Figure 03: Global Human Papillomavirus Vaccine Market Value Share, by Valence, 2022

    Figure 04: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Indication, 2022

    Figure 05: Global Human Papillomavirus Vaccine Market Value Share, by Indication, 2022

    Figure 06: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 07: Global Human Papillomavirus Vaccine Market Value Share, by Distribution Channel, 2022

    Figure 08: Global Human Papillomavirus Vaccine Market Value Share, by Region, 2022

    Figure 09: Global Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast, 2017–2031

    Figure 10: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 11: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031

    Figure 12: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 13: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 14: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 15: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 16: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Region, 2017 and 2031

    Figure 17: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Region, 2023-2031

    Figure 18: North America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Country, 2017 and 2031

    Figure 21: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 22: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 23: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 24: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

    Figure 25: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 26: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 27: Europe Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 30: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 31: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 32: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 33: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

    Figure 34: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 35: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 36: Asia Pacific Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 39: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 40: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 41: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 42: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

    Figure 43: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 44: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 45: Latin America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 48: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 49: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 50: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 51: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

    Figure 52: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031

    Figure 53: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 54: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 57: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031

    Figure 58: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031

    Figure 59: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031

    Figure 60: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031

    Figure 61: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 62: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved